“`html
Immunovant (Nasdaq: IMVT) has announced compelling six-month remission data for batoclimab in the treatment of uncontrolled Graves’ disease, signaling a potential paradigm shift in managing this autoimmune disorder. Data from a proof-of-concept study reveals that approximately 80% (17 out of 21) of patients maintained normal thyroid function six months after cessation of batoclimab treatment, with an impressive 50% (8 out of 17) of responders achieving complete remission without the need for anti-thyroid drugs (ATDs).
The study, which involved a 24-week subcutaneous administration of batoclimab followed by a 24-week off-treatment follow-up, showcased remarkable durability. An additional 30% (5 out of 17) of responding patients required only minimal ATD doses, further highlighting the drug’s potential. The safety and tolerability profile remained consistent with earlier batoclimab trials.
Immunovant’s lead compound, IMVT-1402, is currently undergoing evaluation in two potentially registrational trials, with topline results anticipated in 2027. The company is betting on the promise of FcRn inhibition to address the underlying autoimmune dysfunction in Graves’ disease.
Positive
Strong durability, with 80% of patients maintaining normal thyroid function six months post-treatment
50% of responding patients achieved complete ATD-free remission
An additional 30% of responders required only minimal ATD doses
Potential breakthrough as a disease-modifying therapy for uncontrolled Graves’ disease
Consistent safety and tolerability profile
Negative
Topline results for registrational trials not expected until 2027, creating a longer horizon for potential market entry
The initial study was conducted with a step-down dosing design, which might have slightly impacted the efficacy results
Insights
Roivant’s batoclimab demonstrates remarkable off-treatment durability in Graves’ disease, potentially transforming treatment paradigms.
This data readout from Roivant’s Immunovant subsidiary represents a potentially groundbreaking development in Graves’ disease treatment. The most compelling aspect is the durability of response – approximately 80% of patients maintained normal thyroid function (T3/T4 ≤ ULN) for six months after stopping treatment, suggesting possible disease modification rather than just symptom control.
The anti-thyroid drug (ATD) free remission in 50% of responders is particularly significant. Current standard treatments like ATDs, radioactive iodine, and surgery each have substantial limitations – high relapse rates for ATDs and permanent hypothyroidism for the others. A therapy that induces remission without continued medication represents a paradigm shift.
The data is especially impressive considering these were previously uncontrolled patients who had failed standard ATD therapy. This targets a clear unmet need in the treatment landscape.
From a mechanistic perspective, FcRn blockade represents a novel approach in Graves’ disease. By targeting the recycling of pathogenic autoantibodies rather than just managing symptoms, batoclimab addresses the autoimmune root of the condition.
Importantly, the company is now advancing IMVT-1402, their lead compound, in two potentially registrational trials with a consistent 600 mg dose rather than the step-down approach used with batoclimab. This optimization could potentially yield even stronger durability and remission rates.
The timeline for these trials, with topline readouts expected in 2027, provides a clear development pathway. If successful, this therapeutic approach could transform the standard of care for Graves’ disease patients who currently face limited and often suboptimal treatment options.
09/03/2025 – 01:01 PM
* First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients
* Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up period
* Of the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatment
* Two potentially registrational trials for IMVT-1402 in Graves’ disease are currently enrolling with topline readouts expected in 2027
* Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. EDT
NEW YORK, Sept. 03, 2025 — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company focused on autoimmune diseases, presented six-month off-treatment data on batoclimab in uncontrolled Graves’ disease (GD) at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
“These encouraging results support FcRn blockade as a potential treatment mechanism for Graves’ disease, with remission data suggesting potential disease modification,” said George Kahaly, M.D., Ph.D., Lead Principal Investigator.
“We are excited to present remission data demonstrating strong durability of response and ATD-free remission in previously uncontrolled patients off-treatment for six months,” said Eric Venker, M.D., Pharm.D., CEO of Immunovant. “We believe these data could be transformative for patients, if approved by the FDA, addressing an unmet need in Graves’ disease.”
Graves’ Disease Proof-of-Concept Study
The six-month off-treatment data comes from a proof-of-concept study of batoclimab — Immunovant’s first-generation fully human monoclonal antibody targeting FcRn. The study involved a 24-week treatment period with staggered dosing (Weeks 0-12 at 680 mg weekly (QW) subcutaneously (SC) and Weeks 12-24 at 340 mg QW SC), followed by a 24-week off-treatment follow-up period, in patients with active Graves’ disease documented by elevated thyrotropin receptor autoantibodies (TRAb) and hyperthyroidism despite ATD therapy. The key endpoint was the proportion of participants achieving normalization of free triiodothyronine (T3) and free thyroxine (T4) or T3 / T4 being below the lower limit of normal (LLN) at Week 24, without an increase in ATD dose from baseline.
Graves’ Disease Six-month Remission Data
25 patients were enrolled in the treatment period, with 21 entering the off-treatment 24-week follow-up period:
* At Week 48 (end of the six-month follow-up period), ~80% (17/21) of patients maintained T3/T4 values ≤ upper limit of normal (ULN), indicating strong durability of response through six months off treatment
* Of these 17 patients, ~50% (8/17) were in ATD free-remission and an incremental ~30% (5/17) were on ATD doses of 2.5 mg/day following six months off treatment, even with batoclimab’s suboptimal step-down dosing design during the treatment period
* Safety and tolerability were consistent with prior batoclimab studies
IMVT-1402 Registrational Trial Design
Two potentially registrational trials of Immunovant’s lead compound IMVT-1402 in Graves’ disease will evaluate a 600 mg dose for up to 52 weeks without a step-down in dose.
The two registrational global trials for IMVT-1402 are currently enrolling, with topline readouts expected in 2027.
Investor Conference Call Information
Roivant will host a live conference call and webcast at 4:30 p.m. EDT on Wednesday, September 3, 2025, to discuss these Immunovant data.
About Immunovant, Inc.
Immunovant, Inc. is focused on autoimmune diseases. The Company is developing innovative, targeted therapies designed to meet the needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Forward-Looking Statements
This presentation contains forward-looking statements. The use of words such as “can,” “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” “intend,” “anticipate,” and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include Immunovant’s expectations regarding the clinical and therapeutic benefits of its product candidates, including durability of response, efficacy, tolerability and the potential for disease modification and first-in-class potential; patient enrollment, timing, design, progress, scope and results of its existing and planned clinical trials, including the potential registrational trials for IMVT-1402 in Graves’ disease and whether the trial designs will result in improved efficacy data; future development of IMVT-1402 and batoclimab, including the timing and likelihood of expansion into additional indications; the evolution of the treatment paradigm for Graves’ disease in North America; the size and growth of the potential markets for Immunovant’s product candidates and indication selections, including any estimated market opportunities; expectations regarding the receipt of regulatory approval for its product candidates; and whether, if approved, IMVT-1402 or batcolimab will be successfully distributed, marketed or commercialized. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive of final trial results or of the results of later clinical trials; results of animal studies may not be predictive of results in humans; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this presentation; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the effect of global factors such as geopolitical tensions and adverse macroeconomic conditions on Immunovant’s business operations and supply chains, including its clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval and commercialization of batoclimab and IMVT-1402; Immunovant is in various stages of clinical development for IMVT-1402 and batoclimab; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 11, 2025, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
Media
Stephanie Lee
FAQ
What are the key results from Immunovant’s Graves’ disease treatment study?
The study showed that 80% (17/21) of patients maintained normal thyroid function 6 months after treatment, with 50% (8/17) achieving complete remission without requiring anti-thyroid drugs.
How is batoclimab administered to Graves’ disease patients?
Batoclimab was administered subcutaneously at 680 mg weekly for weeks 0-12, followed by 340 mg weekly for weeks 12-24.
When will Immunovant’s IMVT-1402 registrational trial results be available?
Topline results from the two registrational trials for IMVT-1402 in Graves’ disease are expected in 2027.
What makes Immunovant’s treatment different from existing Graves’ disease therapies?
It is the first-ever potentially disease-modifying therapy for uncontrolled Graves’ disease, showing durability of response and ATD-free remission in previously uncontrolled patients.
What is the dosing protocol for the new IMVT-1402 registrational trials?
The trials will evaluate a 600 mg dose for up to 52 weeks without a step-down in dose, different from the batoclimab study’s step-down approach.
